Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
INSY's Cash to Debt is ranked higher than
95% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. INSY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
INSY' s Cash to Debt Range Over the Past 10 Years
Min: 0.01  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.77
INSY's Equity to Asset is ranked higher than
58% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. INSY: 0.77 )
Ranked among companies with meaningful Equity to Asset only.
INSY' s Equity to Asset Range Over the Past 10 Years
Min: -3.45  Med: 0.80 Max: 0.98
Current: 0.77
-3.45
0.98
Interest Coverage No Debt
INSY's Interest Coverage is ranked higher than
94% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INSY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
INSY' s Interest Coverage Range Over the Past 10 Years
Min: 35.09  Med: 10000.00 Max: 9999.99
Current: No Debt
35.09
9999.99
F-Score: 7
Z-Score: 10.51
M-Score: -3.11
WACC vs ROIC
8.23%
60.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 25.81
INSY's Operating margin (%) is ranked higher than
89% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. INSY: 25.81 )
Ranked among companies with meaningful Operating margin (%) only.
INSY' s Operating margin (%) Range Over the Past 10 Years
Min: -324863.64  Med: -151.46 Max: 32.79
Current: 25.81
-324863.64
32.79
Net-margin (%) 16.42
INSY's Net-margin (%) is ranked higher than
86% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. INSY: 16.42 )
Ranked among companies with meaningful Net-margin (%) only.
INSY' s Net-margin (%) Range Over the Past 10 Years
Min: -301890.91  Med: -157.52 Max: 40.67
Current: 16.42
-301890.91
40.67
ROE (%) 23.42
INSY's ROE (%) is ranked higher than
94% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. INSY: 23.42 )
Ranked among companies with meaningful ROE (%) only.
INSY' s ROE (%) Range Over the Past 10 Years
Min: -130.7  Med: -46.69 Max: 545.67
Current: 23.42
-130.7
545.67
ROA (%) 17.48
INSY's ROA (%) is ranked higher than
95% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. INSY: 17.48 )
Ranked among companies with meaningful ROA (%) only.
INSY' s ROA (%) Range Over the Past 10 Years
Min: -118.94  Med: -54.65 Max: 67.69
Current: 17.48
-118.94
67.69
ROC (Joel Greenblatt) (%) 175.36
INSY's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. INSY: 175.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INSY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2087.93  Med: -1261.67 Max: 203.36
Current: 175.36
-2087.93
203.36
Revenue Growth (3Y)(%) 99.00
INSY's Revenue Growth (3Y)(%) is ranked higher than
95% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. INSY: 99.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INSY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -66.85 Max: 500
Current: 99
0
500
» INSY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-06)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

INSY Guru Trades in Q2 2015

Jim Simons 140,700 sh (+784.91%)
Paul Tudor Jones 14,030 sh (+207.00%)
Steven Cohen Sold Out
» More
Q3 2015

INSY Guru Trades in Q3 2015

Paul Tudor Jones 18,532 sh (+32.09%)
Jim Simons 72,700 sh (-48.33%)
» More
Q4 2015

INSY Guru Trades in Q4 2015

Joel Greenblatt 830,540 sh (New)
John Hussman 75,000 sh (New)
Paul Tudor Jones 26,517 sh (+43.09%)
Jim Simons Sold Out
» More
Q1 2016

INSY Guru Trades in Q1 2016

Joel Greenblatt 1,065,310 sh (+28.27%)
Paul Tudor Jones Sold Out
John Hussman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with INSY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:SHSE:600161, XAMS:GLPG, HKSE:00570, SZSE:002287, XKRX:086900, NAS:TSRO » details
Traded in other countries:NPR1.Germany,
Insys Therapeutics Inc is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. Its two marketed products include Subsys and Dronabinol SG Capsule.

Insys Therapeutics Inc was incorporated in Delaware in June 1990. The Company is a commercial-stage specialty pharmaceutical company. It develops and commercializes supportive care products. The Company has two marketed products Subsys and Dronabinol SG Capsule. Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting, or CINV, and anorexia associated with weight loss in patients with AIDS. It markets Subsys through an incentive-based sales model. Dronabinol SG Capsule is a dronabinol soft gelatin capsule that is a generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS, offered in 2.5, 5.0 and 10.0 milligram dosages. The Company produces the Active Pharmaceutical Ingredient (API) for Dronabinol SG Capsule at its U.S.-based, state-of-the-art dronabinol manufacturing facility. The Company is subject to regulation by the FDA.

Ratios

vs
industry
vs
history
P/E(ttm) 22.96
INSY's P/E(ttm) is ranked higher than
64% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.15 vs. INSY: 22.96 )
Ranked among companies with meaningful P/E(ttm) only.
INSY' s P/E(ttm) Range Over the Past 10 Years
Min: 17.67  Med: 35.93 Max: 2102.86
Current: 22.96
17.67
2102.86
Forward P/E 8.88
INSY's Forward P/E is ranked higher than
84% of the 94 Companies
in the Global Biotechnology industry.

( Industry Median: 17.15 vs. INSY: 8.88 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.96
INSY's PE(NRI) is ranked higher than
64% of the 244 Companies
in the Global Biotechnology industry.

( Industry Median: 30.43 vs. INSY: 22.96 )
Ranked among companies with meaningful PE(NRI) only.
INSY' s PE(NRI) Range Over the Past 10 Years
Min: 17.81  Med: 35.69 Max: 736
Current: 22.96
17.81
736
Price/Owner Earnings (ttm) 11.90
INSY's Price/Owner Earnings (ttm) is ranked higher than
83% of the 146 Companies
in the Global Biotechnology industry.

( Industry Median: 37.01 vs. INSY: 11.90 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
INSY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.66  Med: 25.26 Max: 161.76
Current: 11.9
9.66
161.76
P/B 4.56
INSY's P/B is ranked lower than
60% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. INSY: 4.56 )
Ranked among companies with meaningful P/B only.
INSY' s P/B Range Over the Past 10 Years
Min: 0.06  Med: 1.84 Max: 19.87
Current: 4.56
0.06
19.87
P/S 3.67
INSY's P/S is ranked higher than
81% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. INSY: 3.67 )
Ranked among companies with meaningful P/S only.
INSY' s P/S Range Over the Past 10 Years
Min: 1.74  Med: 2170.00 Max: 29890
Current: 3.67
1.74
29890
PFCF 14.03
INSY's PFCF is ranked higher than
77% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 26.95 vs. INSY: 14.03 )
Ranked among companies with meaningful PFCF only.
INSY' s PFCF Range Over the Past 10 Years
Min: 11.4  Med: 50.11 Max: 167.27
Current: 14.03
11.4
167.27
POCF 12.38
INSY's POCF is ranked higher than
79% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 24.65 vs. INSY: 12.38 )
Ranked among companies with meaningful POCF only.
INSY' s POCF Range Over the Past 10 Years
Min: 10.05  Med: 33.58 Max: 1288.75
Current: 12.38
10.05
1288.75
EV-to-EBIT 11.57
INSY's EV-to-EBIT is ranked higher than
71% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 24.27 vs. INSY: 11.57 )
Ranked among companies with meaningful EV-to-EBIT only.
INSY' s EV-to-EBIT Range Over the Past 10 Years
Min: -130.9  Med: 0.60 Max: 82.9
Current: 11.57
-130.9
82.9
EV-to-EBITDA 10.84
INSY's EV-to-EBITDA is ranked higher than
73% of the 304 Companies
in the Global Biotechnology industry.

( Industry Median: 21.30 vs. INSY: 10.84 )
Ranked among companies with meaningful EV-to-EBITDA only.
INSY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -228.4  Med: 0.60 Max: 72.1
Current: 10.84
-228.4
72.1
Current Ratio 3.27
INSY's Current Ratio is ranked lower than
61% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. INSY: 3.27 )
Ranked among companies with meaningful Current Ratio only.
INSY' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 6.80 Max: 318.82
Current: 3.27
0.14
318.82
Quick Ratio 2.79
INSY's Quick Ratio is ranked lower than
64% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. INSY: 2.79 )
Ranked among companies with meaningful Quick Ratio only.
INSY' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 6.80 Max: 318.82
Current: 2.79
0.06
318.82
Days Inventory 495.66
INSY's Days Inventory is ranked lower than
95% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. INSY: 495.66 )
Ranked among companies with meaningful Days Inventory only.
INSY' s Days Inventory Range Over the Past 10 Years
Min: 169.77  Med: 398.57 Max: 1095
Current: 495.66
169.77
1095
Days Sales Outstanding 23.76
INSY's Days Sales Outstanding is ranked higher than
80% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. INSY: 23.76 )
Ranked among companies with meaningful Days Sales Outstanding only.
INSY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.67  Med: 48.55 Max: 72.85
Current: 23.76
0.67
72.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.77
INSY's Price/Net Cash is ranked lower than
73% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. INSY: 12.77 )
Ranked among companies with meaningful Price/Net Cash only.
INSY' s Price/Net Cash Range Over the Past 10 Years
Min: 1  Med: 8.77 Max: 69.25
Current: 12.77
1
69.25
Price/Net Current Asset Value 7.76
INSY's Price/Net Current Asset Value is ranked lower than
62% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. INSY: 7.76 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
INSY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.98  Med: 8.21 Max: 91.93
Current: 7.76
0.98
91.93
Price/Tangible Book 4.52
INSY's Price/Tangible Book is ranked lower than
52% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. INSY: 4.52 )
Ranked among companies with meaningful Price/Tangible Book only.
INSY' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.62  Med: 6.72 Max: 84.45
Current: 4.52
0.62
84.45
Price/Projected FCF 2.99
INSY's Price/Projected FCF is ranked higher than
64% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. INSY: 2.99 )
Ranked among companies with meaningful Price/Projected FCF only.
INSY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.99  Med: 6.92 Max: 43.39
Current: 2.99
1.99
43.39
Price/Graham Number 2.15
INSY's Price/Graham Number is ranked higher than
68% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 3.11 vs. INSY: 2.15 )
Ranked among companies with meaningful Price/Graham Number only.
INSY' s Price/Graham Number Range Over the Past 10 Years
Min: 2.17  Med: 4.48 Max: 20.1
Current: 2.15
2.17
20.1
Earnings Yield (Greenblatt) (%) 8.62
INSY's Earnings Yield (Greenblatt) (%) is ranked higher than
92% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. INSY: 8.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INSY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.2  Med: 127.50 Max: 3024.5
Current: 8.62
1.2
3024.5

More Statistics

Revenue (TTM) (Mil) $322.0
EPS (TTM) $ 0.69
Beta0.85
Short Percentage of Float155.43%
52-Week Range $12.21 - 46.17
Shares Outstanding (Mil)71.55

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 321 452 589
EPS ($) 0.72 1.84 2.69
EPS without NRI ($) 0.72 1.84 2.69
EPS Growth Rate
(3Y to 5Y Estimate)
28.00%
» More Articles for NAS:INSY

Headlines

Articles On GuruFocus.com
Comments on the Blockbuster Valeant Conference Call Oct 30 2015 

More From Other Websites
Insys Therapeutics, Inc. to Present at Two Upcoming Conferences in June May 26 2016
INSYS Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : INSY-US : May 26,... May 26 2016
6:51 am Insys Therapeutics announces 'successful' completion of phase 1/phase 2 safety &... May 24 2016
Insys Therapeutics Successfully Completes Safety and Pharmacokinetic (PK) Study of Cannabidiol Oral... May 24 2016
4 Top Stocks in the Growing Medical Marijuana Industry May 18 2016
4 Best Stocks in the Thriving Medical Marijuana Industry May 18 2016
Repros Announces the Appointment of Mr. Patrick Fourteau as Chairman of the Board May 16 2016
INSYS THERAPEUTICS, INC. Financials May 12 2016
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... May 09 2016
INSYS THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report May 05 2016
INSYS Therapeutics, Inc. :INSY-US: Earnings Analysis: Q1, 2016 By the Numbers May 02 2016
Edited Transcript of INSY earnings conference call or presentation 28-Apr-16 2:00pm GMT Apr 28 2016
Insys Therapeutics beats Street 1Q forecasts Apr 28 2016
Insys Therapeutics beats Street 1Q forecasts Apr 28 2016
INSYS THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 28 2016
Q1 2016 INSYS Therapeutics Inc Earnings Release - Before Market Open Apr 28 2016
Insys Therapeutics Reports First Quarter 2016 Results Apr 28 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)